Repository logo
 
Publication

Chondroitin sulphate microparticles for tuberculosis treatment: a way to target macrophages

dc.contributor.authorRodrigues, Susana
dc.contributor.authorRosa Da Costa, Ana
dc.contributor.authorGrenha, Ana
dc.date.accessioned2019-11-20T15:07:28Z
dc.date.available2019-11-20T15:07:28Z
dc.date.issued2017-08
dc.description.abstractTuberculosis remains a leading cause of death; therapeutic failure being mainly due to non-compliance with prolonged treatments, often associated with severe side-effects. New therapeutic strategies are demanded and, considering that the lung is the primary site of infection, direct lung delivery of antibiotics is an interesting and, possibly, effective approach. Therapeutic success in this context depends on suitable carriers that reach the alveoli where Mycobacterium hosts (macrophages) reside, as well as on their ability to promote macrophage capture and intracellular accumulation of drugs. In this work, we propose inhalable chondroitin sulphate microparticles produced by spray-drying and tailored to suitable aerodynamic properties to reach the alveoli. Macrophage targeting will be driven by microparticle size, which is favoured for carriers of 1-2 μm, and composition based on chondroitin sulphate, a glycosaminoglycan comprised of alternating units of sulphated N-acetylgalactosamine and glucuronic acid residues, the former recognized by macrophage receptors. Spray-drying of chondroitin sulphate in combination with two first-line antitubercular drugs (isoniazid and rifabutin) was successful with a satisfactory production yield (> 70%). Microparticles have Feret’s diameter of 1.6 μm, potentiating macrophage uptake. Chondroitin sulphate as solution or microparticulate form and drug-loaded microparticles appear to not have a cytotoxic effect on alveolar epithelial cells. A more extended biocompatibility/safety assessment of this formulation needs to be performed. Taking into account the general trend of the results obtained so far, good indications are given that encourage the continuation of the studies in order to establish the potential of these microparticles as inhalable carriers in tuberculosis treatment.
dc.identifier.issn1941-2711
dc.identifier.issn1941-2703
dc.identifier.urihttp://hdl.handle.net/10400.1/13053
dc.language.isoeng
dc.peerreviewedyes
dc.publisherMary Ann Liebert, Inc
dc.relationSFRH/BD/52426/2013
dc.relationFighting TB: Development of microparticulate systems to target alveolar macrophages in tuberculosis therapy
dc.titleChondroitin sulphate microparticles for tuberculosis treatment: a way to target macrophages
dc.typeconference object
dspace.entity.typePublication
oaire.awardTitleFighting TB: Development of microparticulate systems to target alveolar macrophages in tuberculosis therapy
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FDTP-FTO%2F0094%2F2012/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/5876/UID%2FMulti%2F04326%2F2013/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/5876/UID%2FBIM%2F04773%2F2013/PT
oaire.citation.endPageA22
oaire.citation.issue4
oaire.citation.startPageA21
oaire.citation.titleJournal of Aerosol Medicine and Pulmonary Drug Delivery
oaire.citation.volume30
oaire.fundingStream3599-PPCDT
oaire.fundingStream5876
oaire.fundingStream5876
person.familyNameRodrigues
person.familyNameRosa da Costa
person.familyNameGrenha
person.givenNameSusana
person.givenNameAna M
person.givenNameAna
person.identifier305029
person.identifier.ciencia-id9D1A-6537-0383
person.identifier.ciencia-idA418-A85E-5DB1
person.identifier.ciencia-id091C-0D58-7225
person.identifier.orcid0000-0002-0329-4265
person.identifier.orcid0000-0003-0225-9537
person.identifier.orcid0000-0002-2136-1396
person.identifier.ridE-2165-2012
person.identifier.ridH-1392-2017
person.identifier.scopus-author-id55125292100
person.identifier.scopus-author-id53986075100
person.identifier.scopus-author-id8607930100
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsrestrictedAccess
rcaap.typeconferenceObject
relation.isAuthorOfPublicationf7e806c8-708d-4caf-9b95-cfe9f3b06e8e
relation.isAuthorOfPublication0ca8c16f-6881-4662-bafc-cc51c5ce8d88
relation.isAuthorOfPublication1bd4d8f1-40e5-45af-b1e8-4b8e73a6a70d
relation.isAuthorOfPublication.latestForDiscovery1bd4d8f1-40e5-45af-b1e8-4b8e73a6a70d
relation.isProjectOfPublication0d670626-9c73-4df8-b1ce-45987ba99ed5
relation.isProjectOfPublication868b4818-3efa-4edb-9202-c464d64fd38f
relation.isProjectOfPublicatione13142f2-37b8-4b5a-b2cd-352e62003184
relation.isProjectOfPublication.latestForDiscovery0d670626-9c73-4df8-b1ce-45987ba99ed5

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Rodrigues 2017 DDL abstract.pdf
Size:
253.23 KB
Format:
Adobe Portable Document Format